This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
EGFR Gene Mutation
and you are
between 18 and 75
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential treatment with EGFR-TKIs and chemotherapy in patients with EGFR(Epidermal Growth Factor Receptor)-mutant non-small-cell lung cancer (NSCLC).

Provided treatments

  • Drug: pemetrexed
  • Drug: cisplatin
  • Drug: Erlotinib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02886195. The sponsor of the trial is Fujian Cancer Hospital and it is looking for 120 volunteers for the current phase.
Official trial title:
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC